Patent · US Active

Prodrugs of riluzole and their method of use

US10562870B2 · kind B2 · utility

2Cited by

6References

3Claims

0Family size

Assignee

Biohaven Pharmaceutical Holding Company Ltd. · US

Inventors

Garry Robert Smith · Royersford, US
Allen B. Reitz · Lansdale, US
Mark McDonnell · Lansdale, US
Suzie Chen · Highland Park, US
Matthew D. Vera · West Haverstraw, US
Benjamin E. Blass · Eagleville, US
Jeffery Claude Pelletier · Marble Hall, US
Venkata Velvadapu · Ankeny, US
Jay E. Wrobel · Lawrenceville, US

Key dates

Filing date	Aug 4, 2017
Grant date	Feb 18, 2020
Priority date	—
Expiry date	Aug 4, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/12
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.